Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine)

The early and massive vaccination campaign in Israel with the mRNA-LNP Comirnaty® (Pfizer-BioNTech) vaccine against the SARS-CoV-2 virus made available large amounts of data regarding the efficacy and safety of this vaccine. Adverse reactions to mRNA-based SARS-CoV-2 vaccines are rare events, but du...

Descripción completa

Detalles Bibliográficos
Autores principales: Bavli, Yaelle, Chen, Bing-Mae, Gross, Guy, Hershko, Alon, Turjeman, Keren, Roffler, Steve, Barenholz, Yechezkel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838877/
https://www.ncbi.nlm.nih.gov/pubmed/36549393
http://dx.doi.org/10.1016/j.jconrel.2022.12.039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838877/
https://www.ncbi.nlm.nih.gov/pubmed/36549393
http://dx.doi.org/10.1016/j.jconrel.2022.12.039

Ejemplares similares